North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.

Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.

SAN FRANCISCO & COLUMBUS, Ohio--(BUSINESS WIRE)--Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, ...

Viral vectors are gaining increasing importance in various medical applications. Among the different types of viral vectors, adenoviral (Ad) vectors have been used for a long time and have now ...

Adenoviral vectors will transduce a wide range of target cells resulting in high-level gene expression. They are non-integrating vectors so expression in dividing cells is progressively lost. First ...

DNA-based information is a new field hoping to fill the gap in long-term data storage by using DNA as an information storage medium. Despite DNA’s potential, researchers face problems accurately ...

Plasmid DNA isolation is an important technique in molecular biology, however, achieving effective high-throughput automation of this method has proven to be challenging. Analytik Jena and SynbiCITE ...

Genes responsible for antimicrobial resistance (AMR) can spread from microbe to microbe through circular genetic material called plasmids, and this lateral transfer occurs in the gut. This week in ...

OXFORD, England--(BUSINESS WIRE)--OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free ...